The FDA adverse-event record for quail

Quail Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 12 adverse event reports for Quail, distributed across 0 distinct breeds currently tracked in the system. Of those reports, 10 involved a death outcome, producing a 83.3% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Quail are Death (10 reports), NT - Abnormal necropsy finding NOS (3 reports), Adipsia (1 reports), Quadriplegia (1 reports), with Death leading the reaction traffic at 10 submissions. On the product side, Monensin Sodium is the single most-referenced drug with 6 reports, followed by Monensin (1), Lufenuron + Milbemycin Oxime (1), Fenbendazol Suspension (1). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Quail reporting patterns against other companion animals in the dataset.

Of the 13 Quail reports with a coded outcome, Died accounts for the largest share at 76.9%. Annual submission volume spans 2,010 to 2,024 reports across the 7 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 0 tracked quail breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.